Search

Your search keyword '"Ruffo, Giovan Battista"' showing total 32 results

Search Constraints

Start Over You searched for: Author "Ruffo, Giovan Battista" Remove constraint Author: "Ruffo, Giovan Battista"
32 results on '"Ruffo, Giovan Battista"'

Search Results

4. Nephrological Complications in Hemoglobinopathies: SITE Good Practice.

5. Current challenges in the management of patients with sickle cell disease – A report of the Italian experience

7. Italian patients with hemoglobinopathies exhibit a 5‐fold increase in age‐standardized lethality due to SARS‐CoV‐2 infection

9. Uncertain crisis time affects psychosocial dimensions in beta-thalassemia patients during Covid-19 pandemic: A cross-sectional study.

11. Non-transfusion-dependent thalassemia in Italy: less blues, no role of reds

12. Additional file 1 of Two-year long safety and efficacy of deferasirox film-coated tablets in patients with thalassemia or lower/intermediate risk MDS: phase 3 results from a subset of patients previously treated with deferasirox in the ECLIPSE study

13. Association between Native Myocardial T1 Mapping and Cardiac Function and Macroscopic Fibrosis in Thalassemia Major

14. Italian patients with hemoglobinopathies exhibit a 5‐fold increase in age‐standardized lethality due to SARS‐CoV‐2 infection.

15. Long‐term sequential deferiprone and deferasirox therapy in transfusion‐dependent thalassaemia patients: a prospective clinical trial

18. Recombinant erythropoietin vs. blood transfusion care in infants with hereditary spherocytosis: a retrospective cohort study of A.I.E.O.P. patients (Associazione Italiana Emato-Oncologia Pediatrica)

19. New film‐coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower‐risk MDS: Results of the randomized, phase II ECLIPSE study

20. New Film-Coated Tablet Formulation of Deferasirox Is Well Tolerated in Patients with Thalassemia or MDS: Results of the Randomized, Phase II E.C.L.I.P.S.E. Study

21. Improved Patient-Reported Outcomes with a Film-Coated Versus Dispersible Tablet Formulation of Deferasirox: Results from the Randomized, Phase II E.C.L.I.P.S.E. Study

22. Luspatercept in the Treatment of Beta Thalassemia in Italy: Lights and Shadows in Clinical Practice

23. Improvement of heart iron with preserved patterns of iron store by CMR-guided chelation therapy

24. Myocardial iron overload in thalassemia major. How early to check?

25. Myocardial Iron overload In Thalassemia Major. how Early To Check?

26. Myocardial and Hepatic Iron Overload and Cardiac Function In Sickle/Thalassemia Patients Of Italian Origin

27. Myocardial iron overload in sickle/thalassemia patients of Italian origin

29. Italian patients with hemoglobinopathies exhibit a 5-fold increase in age-standardized lethality due to SARS-CoV-2 infection

30. New film‐coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower‐risk MDS: Results of the randomized, phase II ECLIPSE study

31. Recombinant erythropoietin vs. blood transfusion care in infants with hereditary spherocytosis: a retrospective cohort study of A.I.E.O.P. patients (Associazione Italiana Emato-Oncologia Pediatrica)

32. Improvement of heart iron with preserved patterns of iron store by CMR-guided chelation therapy.

Catalog

Books, media, physical & digital resources